Amycretin vs Wegovy: What’s the Difference?
Amycretin vs Wegovy: A New Chapter in Weight Loss Medication
With obesity rates continuing to climb, the demand for effective weight loss treatments has surged. Among the most talked-about solutions are Amycretin and Wegovy – two injectable medications that target GLP-1 pathways to help people shed weight. But how do they compare? Here’s everything you need to know about these weight loss contenders.
What Is Wegovy?
Wegovy (semaglutide) is a GLP-1 receptor agonist developed by Novo Nordisk, originally used for managing type 2 diabetes under the brand name Ozempic. It was later approved for weight loss due to its potent effect on appetite regulation.
- Mechanism: Mimics GLP-1 (Glucagon-like peptide-1) to reduce hunger and slow digestion
- Dosing: Once-weekly injection
- Approved Use: Obesity treatment in adults with BMI ≥30 or ≥27 with comorbidities
Effectiveness: Up to 15% body weight reduction in trials
What Is Amycretin?
Amycretin is a new investigational weight loss drug developed by Novo Nordisk as part of its next-generation pipeline. Unlike Wegovy, Amycretin is a dual agonist, targeting both GLP-1 and amylin receptors.
- Mechanism: Combines GLP-1 and amylin pathway activation for enhanced satiety and slowed gastric emptying
- Dosing: Once-weekly injection (pending final approval)
- Clinical Stage: Currently undergoing trials; not yet available commercially
Early Results: Patients have lost up to 24% of their body weight in Phase 1 trials (compared to 15% with Wegovy)
Amycretin’s unique mechanism of action is still being explored in clinical trials, but early results show promise. If you’d like a complete guide on Amycretin’s weight loss benefits, dosage details, and how to get it in the UK, you can read our in-depth breakdown here: Amycretin Weight Loss Injection UK.
Key Differences Between Amycretin and Wegovy
| Feature | Wegovy | Amycretin (Investigational) |
| Developer | Novo Nordisk | Novo Nordisk |
| Mechanism | GLP-1 receptor agonist | GLP-1 + Amylin receptor dual agonist |
| Weight Loss (avg.) | Up to 15% body weight | Up to 24% in early trials |
| Availability | Available on private Rx in UK | Not yet approved or available |
| Injection Frequency | Weekly | Weekly (expected) |
| Side Effects | Nausea, vomiting, constipation | Similar GI effects expected |
| Commercial Status | Approved for weight loss | Still in clinical trials |
Which One Is Better?
While Wegovy is already available and highly effective, Amycretin has shown even greater promise in early trials. The addition of amylin receptor targeting may further reduce appetite and improve glucose control, making Amycretin a potential game-changer.
However, since Amycretin is still in the research phase, Wegovy remains the go-to treatment for those seeking immediate weight loss support in the UK.
When Will Amycretin Be Available in the UK?
As of mid-2025, Amycretin is still undergoing clinical trials. If results continue to be positive, we may see UK approval by late 2026 or early 2027. It is expected to launch under tight regulation through private clinics and specialist prescribers.
Where Can You Get Wegovy in the UK?
At MedCare Health Clinic & Pharmacy in Preston, we offer:
- Online and in-person consultations
- Fast, discreet delivery of Wegovy (semaglutide)
Aftercare and support throughout your treatment journey
Final Thoughts
Both Wegovy and Amycretin represent the future of weight loss pharmacotherapy. While Wegovy is the current gold standard, Amycretin may soon redefine what’s possible.
Interested in Wegovy now or preparing for Amycretin’s launch? Book a consultation with MedCare Health Clinic to begin your weight loss journey today.